(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.02%) $83.40
(0.08%) $2.48
(0.12%) $2 341.60
(1.57%) $29.76
(0.34%) $992.10
(0.05%) $0.931
(0.17%) $10.67
(0.04%) $0.791
(0.00%) $86.75
@ $157.43
Issued: 1 Jul 2024 @ 14:18
Return: -0.43%
Previous signal: Jul 1 - 10:55
Previous signal:
Return: -1.78 %
Live Chart Being Loaded With Signals
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases...
Stats | |
---|---|
Today's Volume | 1.29M |
Average Volume | 1.74M |
Market Cap | 14.82B |
EPS | $0.380 ( Q1 | 2024-05-01 ) |
Next earnings date | ( $0.0200 ) 2024-08-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
364.53 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $7.77 (4.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-25 | Brown Ryan Edward | Buy | 23 500 | Common Stock |
2024-06-25 | Brown Ryan Edward | Sell | 7 644 | Common Stock |
2024-06-25 | Brown Ryan Edward | Sell | 2 200 | Common Stock |
2024-06-25 | Brown Ryan Edward | Sell | 975 | Common Stock |
2024-06-25 | Brown Ryan Edward | Sell | 4 168 | Common Stock |
INSIDER POWER |
---|
-16.69 |
Last 99 transactions |
Buy: 181 996 | Sell: 393 282 |
Volume Correlation
Sarepta Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
VIA | 0.832 |
10 Most Negative Correlations | |
---|---|
WINT | -0.863 |
EJH | -0.838 |
UTRS | -0.821 |
HQI | -0.82 |
PLL | -0.819 |
TENX | -0.815 |
GLBS | -0.813 |
BKYI | -0.809 |
NMRD | -0.807 |
VRM | -0.806 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sarepta Therapeutics Inc Correlation - Currency/Commodity
Sarepta Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $1.24B |
Gross Profit: | $1.09B (87.91 %) |
EPS: | $-5.80 |
FY | 2023 |
Revenue: | $1.24B |
Gross Profit: | $1.09B (87.91 %) |
EPS: | $-5.80 |
FY | 2022 |
Revenue: | $933.01M |
Gross Profit: | $793.02M (85.00 %) |
EPS: | $-8.03 |
FY | 2021 |
Revenue: | $701.89M |
Gross Profit: | $604.84M (86.17 %) |
EPS: | $-5.15 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators